Osteoprotegerin and osteopontin serum values in postmenopausal advanced breast cancer patients treated with anastrozole

Endocrine-Related Cancer

Volumn 11, Issue 4, 2004, Pages 771-779

  Martinetti, A ^a   Bajetta, E ^a   Ferrari, L ^a   Zilembo, N ^a   Seregni, E ^a   Del Vecchio, M ^a   Longarini, R ^a   La Torre, I ^a   Toffolatti, L ^a   Paleari, D ^a   Bombardieri, E ^a  

^a NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; AMINO TERMINAL TELOPEPTIDE; ANASTROZOLE; AROMATASE INHIBITOR; CARBOXY TERMINAL TELOPEPTIDE; ESTRADIOL; ESTROGEN RECEPTOR; ESTRONE; ESTRONE SULFATE; GLYCOPROTEIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LIGAND; OSTEOCALCIN; OSTEOPONTIN; OSTEOPROTEGERIN; PROGESTERONE RECEPTOR;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BLOOD SAMPLING; BONE METASTASIS; BONE TURNOVER; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG DOSE REGIMEN; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; OUTCOMES RESEARCH; POSTMENOPAUSE; PREDICTION; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DETERMINATION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; REGULATORY MECHANISM; SURVIVAL RATE; TUMOR VASCULARIZATION;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, HORMONAL; BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; GLYCOPROTEINS; HUMANS; MIDDLE AGED; NITRILES; OSTEOPONTIN; OSTEOPROTEGERIN; POSTMENOPAUSE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; RECEPTORS, TUMOR NECROSIS FACTOR; SIALOGLYCOPROTEINS; SURVIVAL ANALYSIS; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL;

EID: 19944426910     PISSN: 13510088     EISSN: None     Source Type: Journal    
DOI: 10.1677/erc.1.00775     Document Type: Article

References (30)

1. Anderson DM, Maraskovsky E, Billingsley WL, Dougall W, Tometsko ME, Roux ER, Teepe MC, DuBose RF, Cosman D & Galibert L 1997 A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function. Nature 390 175-179.
2. Arrighi H, Khosla S, Melton LJ, Riggs BL, Bekker PJ & Dunstan CR 2000 The relationship between circulating osteoprotegerin and estrogen in postmenopausal women. Journal of Bone and Mineral Research 15 S441.
3. Bajetta E, Zilembo N, Bichisao E, Martinetti A, Buzzoni R, Pozzi P, Bidoli P, Ferrari L & Celio L 2000 Tumor response and estrogen suppression in breast cancer patients treated with l aromatase inhibitors. Annals of Oncology 11 1017-1022.
4. Bajetta E, Martinetti A, Zilembo N, Pozzi P, La Torre I, Ferrari L, Seregni E, Longarini R, Salvucci G & Bombardieri E 2002 Biological activity of anastrozole in postmenopausal patients with advanced breast cancer: effects on estrogens and bone metabolism. Annals of Oncology 13 1059-1066.
5. Buzdar A, Nabholtz J, Robertson J, Thürlimann B, Bonneterre J, von Euler M, Steinberg M & Webster A 2000 Anastrozole (Arimidex™) versus tamoxifen as first-line therapy for advanced breast cancer (ABC) in post-menopausal (pm) women - combined analysis from two identically designed multicenter trials. Proceedings of the American Society of Clinical Oncology 19 154a (Abstract 609D).
6. De long PC, Blankenstein MA, Nortier JWR, Slee PHThJ, van de Ven J, van Gorp JMHH, Elbers JRJ, Schipper MEI, Blijham GH, Thijssen JHH, Lu Q, Jelovac D & Brodie AM 2003 The relationship between aromatase in primary breast tumors and response to treatment with aromatase inhibitors in advanced disease. Journal of Steroid Biochemistry and Molecular Biology 87 149-155.
7. Dodds RA, Connor JR, James IE, Rykaczewski EL, Appelbaum E, Dul E & Gowen M 1995 Human osteoclasts, not osteoblasts, deposit osteopontin onto resorption surfaces: an in vitro and ex vivo study of remodeling bone. Journal of Bone and Mineral Research 10 1666-1680.
8. Eastell R & Adams J 2003 Bone mineral density and bone marker subprotocol. In History and Advancement of Anastrozole in the Treatment of Breast Cancer, Ch 11. Eds A Buzdar & M Baum. London: Royal Society of Medicine.
9. Ferrari L, Bajetta E, Martinetti A, Celio L, Longarini R, La Torre I, Buzzoni R, Gattinoni L, Seregni E & Bombardieri E 2003 Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure of aminogluthimide, anastrozole or letrozole? International Journal of Oncology 22 1081-1089.
10. Furger AK, Menon RK, Tuck AB, Bramwell VHC & Chambers AF 2001 The functional and clinical roles of osteopontin in cancer and metastasis. Current Molecular Medicine 1 621-632.
11. Hamilton A & Piccart M 1999 The third-generation non-steroidal aromatase inhibitors: a review of their clinical benefits in the second-line hormonal treatment of advanced breast cancer. Annals of Oncology 10 377-384.
12. Heshmati HM, Khosla S, Robins SP, O'Fallon WM, Melton LJ III & Riggs BL 2002 Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women. Journal of Bone and Mineral Research 17 172-178.
13. Hofbauer LC, Khosla S, Dunstan CR, Lacey DL, Spelsberg TC & Riggs BL 1999 Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells. Endocrinology 140 4367-4370.
14. Jilka RL, Hangoc G, Girasole G, Passen G, Williams DC, Abrams JS, Boyce B, Broxmeyer H & Manolagas SC 1992 Increased osteoclast development after estrogen loss: mediation by interleukin-6. Science 257 88-91.
15. Lønning PE 2004 Aromatase inhibitors in breast cancer. Endocrine-Related Cancer 11 179-189.
16. Marcus R 1998 New perspectives on the skeletal role of estrogen. Journal of Clinical Endocrinology and Metabolism 83 2236-2238.
17. Martinetti A, Zilembo N, Ferrari L, Massimini G, Polli A, La Torre I, Giovanazzi R, Pozzi P, Bidoli P, De Candis D, Seregni E & Bombardieri E 2003 Bone turnover markers and insulin-like growth factor component in metastatic breast cancer: results from a randomized trial of exemestane vs megestrol acetate. Anticancer Research 23 3485-3491.
18. Nabholtz JM, Buzdar A, Pollak M, Harwin W, Burton G, Mangalik A, Steinberg M, Webster A & von Euler M 2000 Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. Journal of Clinical Oncology 18 3758-3767.
19. Nordin BE, Need AG, Bridges A & Horowitz M 1992 Relative contributions of years since menopause, age, and weight to vertebral density in postmenopausal women. Journal of Clinical Endocrinology and Metabolism 74 20-23.
20. Oates AJ, Barraclough R & Rudland PS 1997 The role of osteopontin in tumorigenesis and metastasis. Invasion Metastasis 17 1-15.
21. Plourde PV, Dyroff M & Dukes M 1994 Arimidex: a potent and selective fourth-generation aromatase inhibitor. Breast Cancer Research and Treatment 30 103-111.
22. Riggs BL, Khosla S & Melton LJ 2002 Sex steroid and the construction and conservation of the adult skeleton. Endocrine Reviews 23 279-302.
23. Rudland PS, Platt-Higgings A, El-Tanani M, De Silva Rudland S, Barraclough R, Winstanley JHR, Howitt R & West CR 2002 Prognostic significance of the metastasis-associated protein osteopontin in human breast cancer. Cancer Research 62 3417-3427.
24. Saika M, Inoue D, Kido S & Matsumoto T 2001 17β-Estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-α. Endocrinology 142 2205-2212.
25. Santen JR, Song RX, Zhang Z, Kumar R, Jeng MH, Masamura S, Yue W & Berstein L 2003 Adaptive hypersensitivity to estrogen: mechanism for superiority of aromatase inhibitors over selective estrogen receptor modulators for breast cancer treatment and prevention. Endocrine-Related Cancer 10 111-130.
26. Seregni E, Martinetti A, Ferrari L & Bombardieri E 2001 Clinical utility of biochemical marker of bone remodelling in patients with bone metastases of solid tumors. Quarterly Journal of Nuclear Medicine 45 7-17.
27. Singhal H, Bautista DS, Tonkin KS, O'Malley FP, Tuck AB, Chambers AF & Harris JF 1997 Elevated plasma osteopontin in metastatic breast cancer associated with increased tumor burden and decreased survival. Clinical Cancer Research 3 605-611.
28. Sodek J, Ganss B & McKee MD 2000 Osteopontin. Critical Reviews in Oral Biology and Medicine 11 279-303.
29. Tuck AB & Chambers AF 2001 The role of osteopontin in breast cancer: clinical and experimental studies. Journal of Mammary Gland Biology and Neoplasia 6 419-429.
30. Yano K, Tsuda E, Washida N, Kobayashi F, Goto M, Harada A, Ikeda K, Higashio K & Yamada Y 1999 Immunological characterization of circulating osteoprotegerin/osteoclastogenesis inhibitory factor: increased serum concentrations in postmenopausal women with osteoporosis. Journal of Bone and Mineral Research 14 518-527.